### Learner Notification

**MED Learning Group**

**Visualizing Mechanisms of Bispecific Antibodies in Large B-Cell Lymphomas: Current Efficacy and Safety Data for Application in Relapsed/Refractory Populations**

**July 27, 2023 – July 27, 2024**

**Online**

**Acknowledgement of Financial Commercial Support**

AbbVie, Genmab

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety.  Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

A picture containing drawing

Description automatically generatedIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Analyze the mechanistic features of bispecific antibodies and rationale for use in relapsed/refractory large B-cell lymphomas.
2. Evaluate current clinical trial data informing use of bispecific antibodies in in relapsed/refractory large B-cell lymphomas.
3. Summarize best practices for management of potential adverse events with bispecific antibodies in large B-cell lymphomas in a multidisciplinary practice setting.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Millena | De Brito | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Amanda | Jenkins | NA |
| Melissa A. | Johnson | NA |
| Aimee | Meissner | NA |
| Michael R. | Page | NA |
| Marco | Ruella | Tmunity (Kite), viTToria Biotherapeutic, GLG, Sana, BMS, GSK, Nanostring, Abclon: Consultant |
| Jo | Shultz | NA |
| Lauren | Welch | NA |

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)